[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640013":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":28,"locations":34,"responsibleParty":148,"collaborators":11,"id":150,"slug":151,"hasResults":152,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":11,"eligibilityCriteria":156,"healthyVolunteers":152,"sex":157,"minAge":158,"maxAge":11,"enrollmentInfo":159,"targetDuration":11,"studyType":162,"phases":163,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":55,"whyStopped":11,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":188},{"fullName":5,"class":6},"NEOK Bio, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation","EXPERIMENTAL",null,[13],"Drug: NEOK001",{"label":15,"type":10,"description":11,"interventionNames":16},"Expansion",[17],"Drug: NEOK001 RDE",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","NEOK001","Escalating doses of NEOK001",[9],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"NEOK001 RDE","Recommended Dose of NEOK001 for Expansion",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Willie J Hudson, MS","CONTACT","615-507-4263","whudson@neokbio.com",[35,53,69,84,97,111,121,134],{"facility":36,"status":37,"city":38,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Memorial Sloan Kettering Cancer Center","NOT_YET_RECRUITING","New York","10065","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-74.00597,40.71427,{"lat":46,"lon":45},[49],{"name":50,"role":31,"phone":51,"phoneExt":11,"email":52},"Jamie Walters","917-843-7966","waltersj@mskcc.org",{"facility":54,"status":55,"city":56,"state":57,"zip":58,"country":40,"countryCode":41,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"SCRI Oncology Partners","RECRUITING","Nashville","Tennessee","37203",{"type":43,"coordinates":60},[61,62],-86.78444,36.16589,{"lat":62,"lon":61},[65],{"name":66,"role":31,"phone":67,"phoneExt":11,"email":68},"Tracey Zimmer","972-566-3000","Tracey.Zimmer@scri.com",{"facility":70,"status":37,"city":71,"state":72,"zip":73,"country":40,"countryCode":41,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"NEXT Oncology","Austin","Texas","78758",{"type":43,"coordinates":75},[76,77],-97.74306,30.26715,{"lat":77,"lon":76},[80],{"name":81,"role":31,"phone":82,"phoneExt":11,"email":83},"Heather Watson","737-610-5202","hwatson@nextoncology.com",{"facility":70,"status":37,"city":85,"state":72,"zip":86,"country":40,"countryCode":41,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"Dallas","75039",{"type":43,"coordinates":88},[89,90],-96.80667,32.78306,{"lat":90,"lon":89},[93],{"name":94,"role":31,"phone":95,"phoneExt":11,"email":96},"Mofopefoluwa \"Fope\" Akinwale","972-893-8800","fakinwale@nextoncology.com",{"facility":98,"status":37,"city":99,"state":72,"zip":100,"country":40,"countryCode":41,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"MD Anderson Cancer Center","Houston","77030",{"type":43,"coordinates":102},[103,104],-95.36327,29.76328,{"lat":104,"lon":103},[107],{"name":108,"role":31,"phone":109,"phoneExt":11,"email":110},"Romeena Momin","713-563-1055","RBMomin@mdanderson.org",{"facility":70,"status":37,"city":99,"state":72,"zip":112,"country":40,"countryCode":41,"cosmosGeoPoint":113,"geoPoint":115,"contacts":116},"77054",{"type":43,"coordinates":114},[103,104],{"lat":104,"lon":103},[117],{"name":118,"role":31,"phone":119,"phoneExt":11,"email":120},"Emma Morales","832-384-7912","emorales@nextoncology.com",{"facility":70,"status":55,"city":122,"state":72,"zip":123,"country":40,"countryCode":41,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"San Antonio","78299",{"type":43,"coordinates":125},[126,127],-98.49363,29.42412,{"lat":127,"lon":126},[130],{"name":131,"role":31,"phone":132,"phoneExt":11,"email":133},"Jordan Georg","210-580-9521","Jgeorg@nextoncology.com",{"facility":70,"status":37,"city":135,"state":136,"zip":137,"country":40,"countryCode":41,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Fairfax","Virginia","22031",{"type":43,"coordinates":139},[140,141],-77.30637,38.84622,{"lat":141,"lon":140},[144],{"name":145,"role":31,"phone":146,"phoneExt":11,"email":147},"Maybelle De La Rosa","703-783-4518","Mdelarosa@nextoncology.com",{"type":149,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100640013","phase-1-a-phase-1-study-of-neok001-a-b7-h3-and-ror1-targeting-bispecific-adc-in-participants-with-select-solid-tumors-100640013",false,"NCT07612176","A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors","A Phase 1 Dose Escalation and Expansion Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific Antibody-Drug Conjugate, in Participants With Select, Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors","Key Inclusion Criteria:\n\n* Participants must have locally advanced or metastatic disease in a select tumor type, for which no standard therapy is available.\n* Participants must have at least 1 measurable target lesion based on RECIST v1.1.\n* Participants must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Participants must have adequate hematologic, hepatic, and renal function.\n* Participants should have available archived tumor tissue from their most recent biopsy.\n\nKey Exclusion Criteria:\n\n* Participant's most recent systemic anti-cancer treatment was an ADC with a topoisomerase 1-inhibitor payload component.\n* Participants with known symptomatic central nervous system (CNS) metastases or any evidence of leptomeningeal disease or evidence of unstable CNS metastases, even if asymptomatic.\n* Participants with a known history of interstitial lung disease (ILD) requiring steroid treatment, or for whom suspected ILD cannot be ruled out by imaging at screening.\n* Participants with clinically severe pulmonary compromise due to intercurrent pulmonary illness and\u002For pulmonary disorder requiring supplemental oxygen or any prior pneumonectomy.\n* Participants with a QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 msec.","ALL","18 Years",{"count":160,"type":161},155,"ESTIMATED","INTERVENTIONAL",[164],"PHASE1","This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).",[167],"Locally Advanced (Unresectable) or Metastatic Solid Tumors",[169,170,171,172,173,174,175,176,177,178],"Antibody-Drug Conjugate","ADC","Bispecific","B7-H3","ROR1","Locally Advanced","Unresectable","Metastatic","Solid Tumor","oncology","2026-05-21",{"date":181,"type":182},"2026-05-28","ACTUAL",{"date":184,"type":182},"2026-04-21",{"date":186,"type":161},"2029-01",{"name":5,"class":6},8]